David Amsellem
Stock Analyst at Piper Sandler
(4.76)
# 131
Out of 5,182 analysts
170
Total ratings
63.5%
Success rate
22.03%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Overweight | $45 → $43 | $33.02 | +30.22% | 9 | Mar 24, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $219 → $232 | $190.94 | +21.50% | 16 | Mar 19, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterates: Overweight | $40 → $41 | $29.33 | +39.79% | 12 | Mar 4, 2026 | |
| PTHS Pelthos Therapeutics | Initiates: Overweight | $48 | $22.74 | +111.08% | 1 | Feb 27, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Overweight | $66 → $75 | $57.67 | +30.05% | 3 | Feb 23, 2026 | |
| AMGN Amgen | Maintains: Overweight | $381 → $432 | $340.00 | +27.06% | 7 | Feb 18, 2026 | |
| ABBV AbbVie | Maintains: Overweight | $289 → $299 | $206.37 | +44.89% | 4 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Neutral | $157 → $177 | $175.61 | +0.79% | 4 | Feb 9, 2026 | |
| VTRS Viatris | Maintains: Neutral | $9 → $12 | $13.16 | -8.81% | 8 | Jan 28, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $148 → $223 | $168.74 | +32.16% | 4 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.32 | +184.81% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $2.31 | +289.61% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $8 | $4.13 | +93.70% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $8 | $5.87 | +36.29% | 6 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 → $13 | $12.32 | +5.52% | 5 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $179 | $130.90 | +36.75% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $50.96 | +27.55% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $20.58 | +21.48% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $41.69 | +190.24% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $6.12 | +194.12% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $32.76 | +12.94% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $9 | $9.60 | -6.25% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $79.47 | -14.43% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $5.26 | -42.97% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.53 | +86.42% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.46 | +506.94% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $27.62 | +52.06% | 3 | Oct 16, 2023 |
Alkermes
Mar 24, 2026
Maintains: Overweight
Price Target: $45 → $43
Current: $33.02
Upside: +30.22%
Jazz Pharmaceuticals
Mar 19, 2026
Maintains: Overweight
Price Target: $219 → $232
Current: $190.94
Upside: +21.50%
Teva Pharmaceutical Industries
Mar 4, 2026
Reiterates: Overweight
Price Target: $40 → $41
Current: $29.33
Upside: +39.79%
Pelthos Therapeutics
Feb 27, 2026
Initiates: Overweight
Price Target: $48
Current: $22.74
Upside: +111.08%
Bristol-Myers Squibb Company
Feb 23, 2026
Maintains: Overweight
Price Target: $66 → $75
Current: $57.67
Upside: +30.05%
Amgen
Feb 18, 2026
Maintains: Overweight
Price Target: $381 → $432
Current: $340.00
Upside: +27.06%
AbbVie
Feb 18, 2026
Maintains: Overweight
Price Target: $289 → $299
Current: $206.37
Upside: +44.89%
Biogen
Feb 9, 2026
Maintains: Neutral
Price Target: $157 → $177
Current: $175.61
Upside: +0.79%
Viatris
Jan 28, 2026
Maintains: Neutral
Price Target: $9 → $12
Current: $13.16
Upside: -8.81%
Axsome Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $148 → $223
Current: $168.74
Upside: +32.16%
Jan 9, 2026
Initiates: Overweight
Price Target: $18
Current: $6.32
Upside: +184.81%
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $2.31
Upside: +289.61%
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.13
Upside: +93.70%
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $5.87
Upside: +36.29%
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.32
Upside: +5.52%
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $130.90
Upside: +36.75%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $50.96
Upside: +27.55%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $20.58
Upside: +21.48%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $41.69
Upside: +190.24%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $6.12
Upside: +194.12%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $32.76
Upside: +12.94%
Mar 21, 2025
Downgrades: Neutral
Price Target: $15 → $9
Current: $9.60
Upside: -6.25%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $79.47
Upside: -14.43%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $5.26
Upside: -42.97%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.53
Upside: +86.42%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.46
Upside: +506.94%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $27.62
Upside: +52.06%